Technical Reports on Biotech Equities -- Amicus Therapeutics, Pulmatrix, Amgen, and Bioverativ

Monday, July 17, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 17, 2017 /PRNewswire/ --

If you want a Stock Review on FOLD, PULM, AMGN or BIVV then come over to and sign up for your free customized report today. is currently evaluating Amicus Therapeutics Inc. (NASDAQ: FOLD), Pulmatrix Inc. (NASDAQ: PULM), Amgen Inc. (NASDAQ: AMGN), and Bioverativ
Inc. (NASDAQ: BIVV). These stocks operate in the Biotech space, which is a notoriously risky business, as per Investopedia. Many biotech products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money. Learn more about these stocks by downloading their comprehensive and free reports from member's area at:

Amicus Therapeutics 

Cranbury, New Jersey headquartered Amicus Therapeutics Inc.'s shares finished Friday's session 2.56% higher at $12.84. A total volume of 3.97 million shares was traded, which was above their three months average volume of 3.24 million shares. The stock has surged 48.78% in the last month, 80.08% over the previous three months, and 158.35% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 44.53% and 76.49%, respectively. Moreover, shares of Amicus Therapeutics, which engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases, have a Relative Strength Index (RSI) of 74.32.

On July 12th, 2017, Amicus Therapeutics announced that it has commenced a $225-million underwritten public offering of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering. FOLD complete research report is just a click away at:


Shares in Lexington, Massachusetts headquartered Pulmatrix Inc. ended the day flat at $2.39 with a total trading volume of 89,982 shares. The stock has skyrocketed 305.08% since the start of this year. The Company's shares are trading 8.11% above their 200-day moving average. Moreover, shares of Pulmatrix, which engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology, have an RSI of 48.80. The complimentary report on PULM can be downloaded at:


Thousand Oaks, California headquartered Amgen Inc.'s stock rose 1.19%, closing the session at $177.13. A total volume of 2.70 million shares was traded. The Company's shares have gained 7.29% in the last one month, 9.60% in the previous three months, and 21.15% on an YTD basis. The stock is trading 7.84% above its 50-day moving average and 10.40% above its 200-day moving average. Additionally, shares of Amgen, which discovers, develops, manufactures, and delivers human therapeutics worldwide, have an RSI of 68.28.

On July 11th, 2017, research firm Jefferies resumed its 'Buy' rating on the Company's stock.

On July 13th, 2017, Amgen and Allergan PLC announced that they will discuss data supporting the ABP 215 Biologics License Application with the Oncologic Drugs Advisory Committee of the US Food and Drug Administration. During the meeting, the former will present a comprehensive data package including the analytical, pharmacokinetic, and clinical data, which will demonstrate that ABP 215 and Avastin® (bevacizumab) are highly similar, with no clinically meaningful differences in terms of the efficacy, safety, and immunogenicity between the products. Sign up for your complimentary research report on AMGN at:


On Friday, shares in Waltham, Massachusetts headquartered Bioverativ Inc. finished the session 0.28% lower at $60.61. A total volume of 1.02 million shares was traded. The stock has gained 5.56% in the last month, 6.65% over the previous three months, and 27.60% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 4.93% and 13.72%, respectively. Moreover, shares of Bioverativ, which focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the US and Japan, have an RSI of 52.96.

On June 30th, 2017, research firm Jefferies resumed its 'Buy' rating on the Company's stock.

On July 07th, 2017, Bioverativ announced that it will report its financial results for Q2 ending June 30th, 2017, on August 02nd, 2017, after the market closes. The press release will be available under the "Investor Relations" section of the Company's website. Additionally, the Company will host a live webcast on August 03rd, 2017, at 8:00 a.m. EDT to discuss the financial results. Get free access to your research report on BIVV at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store